Wave Life Scienc SEC Filings

Wave Life Sciences Ltd. reported insider transactions by its Chief Financial Officer, Kyle Moran, in a Form 4 filing. On December 8–9, 2025, he exercised multiple share options and sold ordinary shares in the company.

The transactions included option exercises coded "M" and sales coded "S" in several tranches. Reported sales used weighted-average prices around $13.20, $15.00–$15.045, and $20.00–$20.22 per share, with the filing noting that detailed price breakdowns are available on request. These trades were carried out under a Rule 10b5-1 trading plan adopted on March 13, 2025.

After the reported transactions, Moran directly beneficially owned 90,365 ordinary shares of Wave Life Sciences and held several fully vested or scheduled-vesting share options with exercise prices ranging from $2.83 to $10.48 per share and expirations between 2030 and 2033.

Wave Life Sciences Ltd. director Mark Corrigan reported open‑market sales of company ordinary shares under a pre‑arranged Rule 10b5‑1 trading plan. On December 8, 2025, he sold 9,600 ordinary shares at a weighted‑average price of $13.09 per share and later the same day sold an additional 6,515 ordinary shares at a weighted‑average price of $14.065 per share. After these transactions, he beneficially owned 35,330 ordinary shares following the first sale and 28,815 ordinary shares following the second, all held directly. The prices for each block reflect multiple individual trades within stated ranges, and full trade‑level details are available from the reporting person upon request.

Wave Life Sciences Ltd. director Christian Henry reported a series of option exercises and share sales in the company’s ordinary shares. On December 8, 2025, he exercised options to buy 42,000 shares at $5.97, 15,000 shares at $3.50, and 30,000 shares at $4.585 per share, all from fully vested options. He then sold 6,445 shares at $12.75, 42,000 shares at $12.75, 15,000 shares at a weighted-average price of $14.07 (with individual trades between $14.00 and $14.14), and 30,000 shares at a weighted-average price of $18.02 (with trades between $18.00 and $18.19). After these transactions, he directly owned 12,700 ordinary shares and retained options for 6,000 shares at $3.50 and 15,000 shares at $4.585. All trades were made under a Rule 10b5-1 trading plan adopted on August 6, 2025.

Wave Life Sciences Ltd. furnished an updated corporate presentation for the investment community. The new presentation, dated November 17, 2025, provides business updates and is available in the Investors section of the company’s website. It is also included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain Exchange Act liabilities or automatically incorporated into other SEC filings.

Wave Life Sciences Ltd. (WVE) director Adrian Rawcliffe reported an open-market sale of company stock. On 11/13/2025, he sold 16,115 ordinary shares of Wave Life Sciences at a weighted-average price of $6.79 per share, in multiple transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2025. After this transaction, the reporting person beneficially owned 12,700 ordinary shares, held directly.

The filing notes that the shares were sold in several trades within a price range of $6.64 to $7.00 per share, and the reporting person has undertaken to provide full details of the number of shares sold at each separate price upon request by the issuer, its security holders, or the SEC staff.

Wave Life Sciences (WVE): RA Capital Healthcare Fund, L.P. and affiliated reporting persons disclosed an open-market purchase of 1,000 ordinary shares on 11/13/2025 at a weighted average price of $6.6875. Following the transaction, they reported 18,203,009 shares beneficially owned indirectly. The purchase was made to extend the period for acquisitions under the fund’s Hart-Scott-Rodino filing. Previously reported 28,815 RSUs granted to Dr. Peter Kolchinsky are held for the benefit of the fund.

Wave Life Sciences Ltd. filed a Form S-8 to register 8,000,000 additional ordinary shares reserved under the Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended. The increase of 8,000,000 shares under the plan was effective August 5, 2025.

The filing registers additional securities of the same class as previously registered on Form S-8 (File No. 333-259196) and incorporates that registration by reference pursuant to General Instruction E. It also incorporates the company’s recent 10-K, 10-Qs, proxy materials, and specified 8-Ks by reference. This is an administrative registration for an employee benefit plan rather than a public offering.

Wave Life Sciences Ltd. registered 300,000 ordinary shares on Form S-8, covering shares issuable upon exercise of options granted to a new employee under an Inducement Non-qualified Share Option Agreement dated May 27, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

This filing adds registered capacity specifically tied to that inducement option grant. It is an administrative step that facilitates the issuance of shares if and when the employee exercises the options.

Wave Life Sciences Ltd. reported Q3 2025 results. Revenue was $7.6 million, primarily from the GSK collaboration, against operating expenses of $64.0 million, resulting in a net loss of $53.9 million (basic and diluted loss per share $0.32). Other income contributed $2.5 million, mainly from interest.

Cash and cash equivalents totaled $196.2 million at September 30, 2025. Net cash used in operating activities for the first nine months was $153.7 million, partly offset by financing inflows including $42.6 million from the at-the-market equity program. Subsequent to quarter-end, the company received an additional $52.1 million in net ATM proceeds.

Deferred revenue was $58.2 million allocated to unsatisfied obligations, with $46.5 million current and $11.7 million long-term. The GSK collaboration recognized $7.6 million in Q3 revenue; a $10.0 million AATD milestone was acknowledged subsequent to quarter-end. Shareholders’ equity was $124.5 million. Ordinary shares outstanding were 167,181,784 as of November 7, 2025.